Labcorp Holdings Inc.

What does Labcorp own?
Labcorp owns the Labcorp diagnostics network of more than 2,000 patient service centers, the Labcorp OnDemand consumer platform, the Invitae genetic testing business, Ovia Health, and its Biopharma Laboratory Services operations serving drug developers.

Is Labcorp publicly traded?
Yes. Labcorp trades on the New York Stock Exchange under ticker LH and is a member of the S&P 500.

Who founded Labcorp?
Labcorp was formed in 1995 through the merger of National Health Laboratories and Roche Biomedical Laboratories. The Burlington predecessor, Biomedical Laboratories, was founded in 1969 by brothers James, Thomas, and John Powell.

Where is Labcorp headquartered?
Labcorp is headquartered in Burlington, North Carolina, USA.

How many brands does Labcorp own?
Its principal brands are Labcorp, Labcorp OnDemand, Invitae, and Ovia Health, alongside enterprise brands serving pharmaceutical clients.

Who owns Labcorp?
Labcorp is an independent public company owned by its shareholders, predominantly institutional investors. No parent company controls it.

Did Labcorp buy Invitae?
Yes. Labcorp acquired select assets of Invitae for $239 million in August 2024 after Invitae filed for Chapter 11 bankruptcy, adding its genetic testing portfolio for oncology and rare diseases.

Labcorp's corporate lineage runs through two predecessor laboratory networks. The Burlington side began in 1969, when Dr. James B. Powell and his brothers Thomas and John founded Biomedical Laboratories in a hospital basement in Burlington, North Carolina. Hoffmann-La Roche acquired the business in 1982 and merged its U.S. laboratory operations into Roche Biomedical Laboratories the following year.

The other half began inside Revlon, which assembled a clinical testing business through acquisitions and renamed it National Health Laboratories in 1974. Under Ronald Perelman's MacAndrews & Forbes ownership after 1985, National Health grew into one of the largest lab networks in the country.

In April 1995, National Health Laboratories Holdings merged with Roche Biomedical Laboratories in a deal valued at roughly $1.3 billion. The combination created Laboratory Corporation of America Holdings, headquartered in Burlington, instantly one of the largest clinical laboratory providers in the world. Roche took a 49.9% stake that it later sold.

The modern era is defined by two large moves. In 2015, under CEO David King, Labcorp acquired Covance, a contract research and drug development company, for approximately $6.1 billion. The deal made Labcorp both a diagnostics company and a major player in pharmaceutical research services. Adam Schechter arrived as CEO in 2019 and, after integrating Covance, concluded the two halves were worth more apart: in June 2023 Labcorp spun off the clinical development business to shareholders as Fortrea, a new public company.

The company kept building on the diagnostics side. It acquired Ovia Health, a women's and family health app, in 2021. In August 2024 it bought select assets of Invitae, the medical genetics company, for $239 million after Invitae filed for Chapter 11. The purchase added hereditary cancer, rare disease, and reproductive genetic testing to the catalog.

FY2025 produced revenue of $13.95 billion, up 7.2% over 2024, with net income of $876.5 million and diluted EPS of $10.46. The company launched more than 130 new tests during the year and leaned into areas such as oncology, women's health, autoimmune disease, and neurology testing.

Labcorp publishes annual corporate responsibility reporting covering laboratory waste, energy use, and employee safety, along with health equity programs aimed at expanding testing access in underserved communities. Its material ethical issues are more often about data and billing than environment.

Genetic privacy is the sensitive area. Both Labcorp and Invitae hold large volumes of patient genetic and health data governed by HIPAA, and the company's data handling draws scrutiny from regulators and privacy advocates. It is not a Certified B Corporation.

Labcorp, like every large U.S. laboratory, operates under continuous CMS and FDA oversight and has paid periodic settlements over billing practices. A 2023 data breach at a third-party vendor exposed information on millions of patients, adding to sector-wide scrutiny of health data security.

The company has also faced litigation over alleged kickback arrangements with hospitals and over prenatal test accuracy claims, most publicly a wrongful birth suit involving an earlier settlement. These matters resolve through standard settlements without material structural impact.

Prenatal and genetic test accuracy lawsuits represent a recurring category of risk for the whole diagnostics industry, and Labcorp discloses such matters in its SEC filings as routine litigation.